Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239292743> ?p ?o ?g. }
Showing items 1 to 72 of
72
with 100 items per page.
- W4239292743 endingPage "456" @default.
- W4239292743 startingPage "440" @default.
- W4239292743 abstract "Rapid progress has been made in interventional cardiology over the past years, and many patients with coronary artery disease, even those with complex lesions, are nowadays being treated with percutaneous coronary interventions (PCI). As a result, a major focus of current cardiovascular research is on reducing negative peri-procedural clinical events associated with PCI, particularly in high-risk patients. Among the most dangerous peri-procedural events are thrombotic complications, leading to recurrent myocardial or cerebral ischaemia, often with fatal outcome. Anticoagulant and antithrombotic treatment, therefore, is an integral part of current PCI strategies. It is needless to say that prevention of procedural thrombotic events with the use of anticoagulants occurs at the expense of severe bleeding complications. Hence, there has been a strong effort over recent years to develop and validate novel anticoagulant regimens that provide protection against thrombotic complications, but have only minor effects on normal haemostasis. Until recently, the standard anticoagulation therapy during PCI consisted in either unfractionated (UFH) or low-molecular-weight heparin (LMWH) that prevent coagulation <italic>indirectly</italic> by activation of antithrombin (AT). Once activated, AT inactivates thrombin and other proteases involved in blood clotting. However, only recently <italic>direct</italic> thrombin inhibitors (DTI) have been introduced as an alternative anticoagulant strategy in patients undergoing PCI. Bivalirudin is the most prominent member of the DTI class, <italic>directly</italic> inhibiting free- and clot-bound thrombin. Use of bivalirudin has recently been shown to result in a significant reduction of bleeding without an increase in thrombotic or ischaemic endpoints compared to heparin and glycoprotein (GP) IIb/IIIa inhibitors in patients presenting with acute coronary syndromes (ACS). This chapter will give an overview of the pharmacology and mechanism of action of bivalirudin and summarize results from recent clinical trials evaluating the use of bivalirudin in patients undergoing PCI." @default.
- W4239292743 created "2022-05-12" @default.
- W4239292743 creator A5007093669 @default.
- W4239292743 creator A5015669756 @default.
- W4239292743 creator A5070212671 @default.
- W4239292743 date "2010-06-01" @default.
- W4239292743 modified "2023-09-25" @default.
- W4239292743 title "The role of bivalirudin in percutaneous coronary intervention" @default.
- W4239292743 doi "https://doi.org/10.1093/med/9780199569083.003.025" @default.
- W4239292743 hasPublicationYear "2010" @default.
- W4239292743 type Work @default.
- W4239292743 citedByCount "0" @default.
- W4239292743 crossrefType "book-chapter" @default.
- W4239292743 hasAuthorship W4239292743A5007093669 @default.
- W4239292743 hasAuthorship W4239292743A5015669756 @default.
- W4239292743 hasAuthorship W4239292743A5070212671 @default.
- W4239292743 hasConcept C126322002 @default.
- W4239292743 hasConcept C164705383 @default.
- W4239292743 hasConcept C2776301958 @default.
- W4239292743 hasConcept C2776710957 @default.
- W4239292743 hasConcept C2776884760 @default.
- W4239292743 hasConcept C2777015399 @default.
- W4239292743 hasConcept C2777292125 @default.
- W4239292743 hasConcept C2777557582 @default.
- W4239292743 hasConcept C2777565915 @default.
- W4239292743 hasConcept C2778205648 @default.
- W4239292743 hasConcept C2778810321 @default.
- W4239292743 hasConcept C2779026020 @default.
- W4239292743 hasConcept C2779161974 @default.
- W4239292743 hasConcept C2780400711 @default.
- W4239292743 hasConcept C45393284 @default.
- W4239292743 hasConcept C500558357 @default.
- W4239292743 hasConcept C57002609 @default.
- W4239292743 hasConcept C71924100 @default.
- W4239292743 hasConcept C89560881 @default.
- W4239292743 hasConceptScore W4239292743C126322002 @default.
- W4239292743 hasConceptScore W4239292743C164705383 @default.
- W4239292743 hasConceptScore W4239292743C2776301958 @default.
- W4239292743 hasConceptScore W4239292743C2776710957 @default.
- W4239292743 hasConceptScore W4239292743C2776884760 @default.
- W4239292743 hasConceptScore W4239292743C2777015399 @default.
- W4239292743 hasConceptScore W4239292743C2777292125 @default.
- W4239292743 hasConceptScore W4239292743C2777557582 @default.
- W4239292743 hasConceptScore W4239292743C2777565915 @default.
- W4239292743 hasConceptScore W4239292743C2778205648 @default.
- W4239292743 hasConceptScore W4239292743C2778810321 @default.
- W4239292743 hasConceptScore W4239292743C2779026020 @default.
- W4239292743 hasConceptScore W4239292743C2779161974 @default.
- W4239292743 hasConceptScore W4239292743C2780400711 @default.
- W4239292743 hasConceptScore W4239292743C45393284 @default.
- W4239292743 hasConceptScore W4239292743C500558357 @default.
- W4239292743 hasConceptScore W4239292743C57002609 @default.
- W4239292743 hasConceptScore W4239292743C71924100 @default.
- W4239292743 hasConceptScore W4239292743C89560881 @default.
- W4239292743 hasLocation W42392927431 @default.
- W4239292743 hasOpenAccess W4239292743 @default.
- W4239292743 hasPrimaryLocation W42392927431 @default.
- W4239292743 hasRelatedWork W10454182 @default.
- W4239292743 hasRelatedWork W12629805 @default.
- W4239292743 hasRelatedWork W1473004 @default.
- W4239292743 hasRelatedWork W1500053 @default.
- W4239292743 hasRelatedWork W1591285 @default.
- W4239292743 hasRelatedWork W19505608 @default.
- W4239292743 hasRelatedWork W20438913 @default.
- W4239292743 hasRelatedWork W5919391 @default.
- W4239292743 hasRelatedWork W9491849 @default.
- W4239292743 hasRelatedWork W5451360 @default.
- W4239292743 isParatext "false" @default.
- W4239292743 isRetracted "false" @default.
- W4239292743 workType "book-chapter" @default.